Ellen Meijer

Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial

Evelien Kneppers, Bronno van der Holt, Marie José Kersten et al. · Blood · 2011 · 193 citations · Full text

Medicine, Hematology, Oncology +16

Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT

Jaime Sanz, Jacques‐Emmanuel Galimard, Myriam Labopin et al. · Journal of Hematology & Oncology · 2020 · 117 citations · Full text

Medicine, Hematology, Oncology +17

Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study

Effie W. Petersdorf, Mary Carrington, Colm Ó’hUigín et al. · The Lancet Haematology · 2019 · 88 citations · Full text

Life Sciences, Hematology, Immunology +17

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

Mohamed Sobh, Mauricette Michallet, Gösta Gahrton et al. · Leukemia · 2016 · 68 citations · Full text

Medicine, Hematology, Oncology +14

Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

Éolia Brissot, Myriam Labopin, Jan J. Cornelissen et al. · Journal of Hematology & Oncology · 2020 · 68 citations · Full text

Life Sciences, Hematology, Immunology +16